Cachexia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. AAVogen, Inc. 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. AB BIosciences 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Acacia Pharma 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. Aphios 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. Artelo Biosciences 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Astellas Pharma Inc. 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. AVEO Pharmaceuticals, Inc 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Cannabics Pharmaceuticals Inc. 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. Extend Biosciences, Inc. 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. GlaxoSmithKline plc 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT 6.11. Xbiotech Inc. 6.11.1. Introduction 6.11.2. Financials 6.11.3. Products and Services 6.11.4. SWOT 6.12. MorphoSys AG 6.12.1. Introduction 6.12.2. Financials 6.12.3. Products and Services 6.12.4. SWOT 6.13. MYOS RENS Technology Inc. 6.13.1. Introduction 6.13.2. Financials 6.13.3. Products and Services 6.13.4. SWOT 6.14. NGM Biopharmaceuticals 6.14.1. Introduction 6.14.2. Financials 6.14.3. Products and Services 6.14.4. SWOT 6.15. Ono Pharmaceutical Co., Ltd. 6.15.1. Introduction 6.15.2. Financials 6.15.3. Products and Services 6.15.4. SWOT 6.16. Paradigm Biopharma 6.16.1. Introduction 6.16.2. Financials 6.16.3. Products and Services 6.16.4. SWOT 6.17. PsiOxus Therapeutics 6.17.1. Introduction 6.17.2. Financials 6.17.3. Products and Services 6.17.4. SWOT 6.18. StemMed, Ltd. 6.18.1. Introduction 6.18.2. Financials 6.18.3. Products and Services 6.18.4. SWOT 6.19. TCI Peptide Therapeutics 6.19.1. Introduction 6.19.2. Financials